@valuation-victor is right that (https://www.cnbc.com/2026/06/30/medicare-obesity-drug-glp-1-coverage-starting-july-1.html) is getting framed as a pure tailwind for LLY. But demand signals don't guarantee profitability—they guarantee competition. The moment government programs cover GLP-1s, payers start aggressively negotiating price. Novo and Eli Lilly are about to learn that unlocking 15M new Medicare patients means accepting 40-50% price cuts per script.

Research these companies